As well as providing easy, free checkups for home patients, Easee now works with a raft of partners in both healthcare and retail, helping to treat patients at the likes of Maastricht UMC+ and UMC Utrecht, whilst teaming with huge retailers like Mister Spex and GrandVision to provide accurate prescriptions for people who want glasses. Not only that, Easee has just kicked off a large multicentre clinical trial to show how it can be used in the aftercare treatment of cataract patients. ‘That medical space is definitely the future for us,’ says Yves. ‘We wanted to start by focusing on the highest volume procedure that there is, and that’s cataracts. All cataract patients have to have multiple checkups after the procedure; our value position is, those checkups could be done from home, and you only come in to see a specialist when there’s a problem.
‘It’s a super simple solution,’ he adds, ‘but because of the volume of cataract patients it provides huge value to society. We actually did a study and assessed that for cataract treatments in The Netherlands alone, replacing physical tests with at-home Easee tests could save €25 million a year.’
With Easee right on the precipice of realising it’s incredible potential, the company was a natural fit for the Rise Program. Though he admits that he’s always been sceptical of accelerator and incubator programs, Yves felt that Techleap was a different proposition. ‘I’ve never been convinced about the amount of time and effort you invest versus what you get out of it,’ he shrugs, ‘but even during the selection process for the Rise Program, I noticed that the Techleap team made a lot of effort to find out about our business and come up with valuable insights and advice for us.
As well as providing easy, free checkups for home patients, Easee now works with a raft of partners in both healthcare and retail, helping to treat patients at the likes of Maastricht UMC+ and UMC Utrecht, whilst teaming with huge retailers like Mister Spex and GrandVision to provide accurate prescriptions for people who want glasses. Not only that, Easee has just kicked off a large multicentre clinical trial to show how it can be used in the aftercare treatment of cataract patients. ‘That medical space is definitely the future for us,’ says Yves. ‘We wanted to start by focusing on the highest volume procedure that there is, and that’s cataracts. All cataract patients have to have multiple checkups after the procedure; our value position is, those checkups could be done from home, and you only come in to see a specialist when there’s a problem.
‘It’s a super simple solution,’ he adds, ‘but because of the volume of cataract patients it provides huge value to society. We actually did a study and assessed that for cataract treatments in The Netherlands alone, replacing physical tests with at-home Easee tests could save €25 million a year.’
With Easee right on the precipice of realising it’s incredible potential, the company was a natural fit for the Rise Program. Though he admits that he’s always been sceptical of accelerator and incubator programs, Yves felt that Techleap was a different proposition. ‘I’ve never been convinced about the amount of time and effort you invest versus what you get out of it,’ he shrugs, ‘but even during the selection process for the Rise Program, I noticed that the Techleap team made a lot of effort to find out about our business and come up with valuable insights and advice for us.